Hosted on MSN2mon
Beam presents new NHP data demonstrating proof-of-concept for ESCAPEESCAPE is comprised of two investigational drug products: BEAM-103, an anti-CD117 monoclonal antibody that is designed to suppress and/or eliminate hematopoietic stem and progenitor cells that ...
BEAM is also working on a preclinical program called ESCAPE, which takes the edited hematopoietic stem cells (ala BEAM-101) but uses an anti-CD117 monoclonal antibody to target diseased blood ...
The company expects to initiate a Phase 1 healthy volunteer clinical trial of BEAM-103, an anti-CD117 monoclonal antibody (mAb) designed to suppress hematopoietic stem and progenitor cells that ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback